Back to top
more

Cyclerion Therapeutics, Inc. (CYCN)

(Delayed Data from NSDQ)

$3.97 USD

3.97
818,489

-0.18 (-4.34%)

Updated Jun 11, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (212 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Fiscal Year End for Cyclerion Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 54 95 0 0 NA
Receivables 0 1 0 0 NA
Notes Receivable 0 0 0 0 NA
Inventories 0 0 0 0 NA
Other Current Assets 4 5 1 1 NA
Total Current Assets 59 101 1 1 NA
Net Property & Equipment 7 12 7 4 NA
Investments & Advances 0 0 0 0 NA
Other Non-Current Assets 0 0 0 0 NA
Deferred Charges 0 0 0 0 NA
Intangibles 0 0 0 0 NA
Deposits & Other Assets 7 6 0 0 NA
Total Assets 115 186 7 5 NA
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 4 0 0 0 NA
Accounts Payable 1 3 3 2 NA
Current Portion Long-Term Debt 0 0 0 0 NA
Current Portion Capital Leases 0 0 0 0 NA
Accrued Expenses 9 12 15 12 NA
Income Taxes Payable 0 0 0 0 NA
Other Current Liabilities 0 0 0 0 NA
Total Current Liabilities 17 18 18 14 NA
Mortgages 0 0 0 0 NA
Deferred Taxes/Income 0 0 0 0 NA
Convertible Debt 0 0 0 0 NA
Long-Term Debt 0 0 0 0 NA
Non-Current Capital Leases 0 0 0 0 NA
Other Non-Current Liabilities 0 0 0 0 NA
Minority Interest (Liabilities) 0 0 0 0 NA
Total Liabilities 56 89 18 14 NA
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 NA
Common Stock (Par) 0 0 0 0 NA
Capital Surplus 223 183 0 0 NA
Retained Earnings -163 -86 0 0 NA
Other Equity 0 0 0 0 NA
Treasury Stock 0 0 0 0 NA
Total Shareholder's Equity 59 98 -10 -9 NA
Total Liabilities & Shareholder's Equity 115 186 7 5 NA
Total Common Equity 59 98 -10 -9 0
Shares Outstanding 33.90 27.40 NA NA NA
Book Value Per Share 1.75 3.57 0.00 0.00 0.00

Fiscal Year End for Cyclerion Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Assets          
Cash & Equivalents 41 54 67 56 67
Receivables 0 0 0 1 1
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 3 4 3 2 2
Total Current Assets 44 59 70 60 70
Net Property & Equipment 7 7 10 11 12
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 7 7 7 6 6
Total Assets 100 115 131 128 140
Liabilities & Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Notes Payable 4 4 4 4 0
Accounts Payable 1 1 2 3 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 5 9 8 7 7
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 13 17 16 16 11
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 52 56 56 62 58
Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 225 223 220 192 187
Retained Earnings -177 -163 -144 -125 -106
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 48 59 75 66 82
Total Liabilities & Shareholder's Equity 100 115 131 128 140
Total Common Equity 48 59 75 66 82
Shares Outstanding 34.10 33.90 33.90 33.90 27.70
Book Value Per Share 1.42 1.75 2.22 1.95 2.94